A case study on how DelveInsight supported a client with a focused CAR-TCR Summit coverage plan to gain exclusive insights into CAR-T therapies for B-cell malignancies.New York, USA, Feb. 21, 2025 (GL ...
UK health technology assessor the National Institute for Health and Care Excellence (NICE) has issued Final Draft Guidance ...
BMS’ Breyanzi and Amgen’s Blincyto will now be available to patients in England with certain types of blood cancer.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果